Open access
Open access
Powered by Google Translator Translator

Chest Medicine (all articles)

Observational study finds a single dose of either Pfizer-BioNTech and Oxford-AstraZeneca vaccines in older adults is about 80% effective at preventing admission to hospital with covid-19.

21 May, 2021 | 08:54h | UTC

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study – The BMJ

Editorial: Effectiveness of England’s initial vaccine roll out – The BMJ

 


M-A: Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens – The pooled prevalence of co-infection at the time of a SARS-CoV-2 diagnosis was 19%, and that of superinfection was 24%.

21 May, 2021 | 08:48h | UTC

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis – PLOS One

 


Report: Face masks effectively limit the probability of SARS-CoV-2 transmission.

21 May, 2021 | 08:49h | UTC

Face masks effectively limit the probability of SARS-CoV-2 transmission – Science

 


AARC Guideline: Management of adult patients with tracheostomy in the acute care setting.

21 May, 2021 | 08:26h | UTC

AARC Clinical Practice Guideline: Management of Adult Patients with Tracheostomy in the Acute Care Setting – Respiratory Care

 


Cohort study: 14% of adults aged 65 years or less who were infected with SARS-CoV-2 had at least one new type of clinical sequelae that required medical care after the acute phase of the illness.

20 May, 2021 | 08:59h | UTC

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study – The BMJ

Editorial: Unpacking post-covid symptoms – The BMJ

 

Commentary on Twitter (thread – click for more)

 


FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination.

20 May, 2021 | 08:55h | UTC

FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination – U.S. Food & Drug Administration

 

Commentary on Twitter (thread – click for more)

 


Systematic review and meta-analysis of observational studies suggest low-dose aspirin may be of benefit for patients with Covid-19 – the finds require further investigation in randomized studies.

20 May, 2021 | 08:54h | UTC

Active Prescription of Low-dose Aspirin During or Prior to Hospitalization and Mortality in COVID-19 — A Systematic Review and Meta-analysis of Adjusted Effect Estimates – International Journal of Infectious Diseases

 


One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

20 May, 2021 | 08:57h | UTC

Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study – Lung

 


Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection

20 May, 2021 | 08:52h | UTC

Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection – JAMA Network Open

Editorial: The Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2 Infection—Another Piece of an Expanding Puzzle

Commentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP

 


ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.

20 May, 2021 | 08:21h | UTC

European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years – European Respiratory Journal

 


[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

19 May, 2021 | 08:51h | UTC

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

 

Commentary on Twitter (thread – click for more)

 


WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

19 May, 2021 | 08:47h | UTC

International COVID-19 trial to restart with focus on immune responses – Nature

 


[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups.

18 May, 2021 | 08:04h | UTC

Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv

Related: [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19

 

Commentary on Twitter

 


#ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.

18 May, 2021 | 08:01h | UTC

AntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology

Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD

Video: Dr. Renato Lopes and Dr. C. Michael Gibson Discuss: Randomized Clinical Trial To Evaluate A Routine Full Anticoagulation Strategy In Patients With Coronavirus Infection (SARS-CoV-2) Admitted To Hospital: The Coalition ACTION Trial

 


COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.

18 May, 2021 | 07:56h | UTC

COVID vaccines can block variant hitting Asia, lab study finds – Nature

See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress

 

Commentary on Twitter

 


SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.

18 May, 2021 | 07:52h | UTC

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy – EClinicalMedicine

 


M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

18 May, 2021 | 07:50h | UTC

Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: A systematic review and meta‐analysis – Mycoses

 


Analysis: Where are we with drug treatments for covid-19?

18 May, 2021 | 07:47h | UTC

Where are we with drug treatments for covid-19? – The BMJ

 


Opinion | E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth.

18 May, 2021 | 07:28h | UTC

E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth – Think Global Health

 

Commentary on Twitter (thread – click for more)

 


Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.

18 May, 2021 | 07:27h | UTC

Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma – Cochrane Library

Summary: Treatment of gastro-oesophageal reflux disease to help manage asthma in adults and children – Cochrane Library

 


RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

17 May, 2021 | 08:56h | UTC

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial – The Lancet

Invited commentary: Convalescent plasma in patients hospitalised with COVID-19

 

Commentaries on Twitter

 


[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.

17 May, 2021 | 08:53h | UTC

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant – The Lancet

News release: Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study – University of Birmingham

Commentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre

 


Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions.

17 May, 2021 | 08:51h | UTC

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study – The BMJ

Commentaries: Expert reaction to study looking at the public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines – Science Media Centre AND Delaying second Covid vaccine doses can save lives, study finds – The Guardian AND Delaying second COVID vaccine dose may prevent deaths under certain conditions – The BMJ

 


#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.

17 May, 2021 | 08:49h | UTC

DARE-19: Dapagliflozin in High-Risk Patients Hospitalized With COVID-19 – American College of Cardiology

See also: Dapagliflozin in Respiratory Failure in Patients With COVID-19 – DARE-19 – American College of Cardiology

 

Commentaries on Twitter

 


‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.

17 May, 2021 | 08:45h | UTC

‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT

Related: COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization – JAMA Oncology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.